First Patient Dosed in Phase 1b Trial of Sitravatinib-Tislelizumab Combo for Advanced Solid Tumors

First Patient Dosed in Phase 1b Trial of Sitravatinib-Tislelizumab Combo for Advanced Solid Tumors
A Phase 1b clinical trial studying a combination of Mirati Therapeutics' small molecule inhibitor sitravatinib and BeiGene's immune checkpoint inhibitor tislelizumab has begun dosing patients. The open-label, multicenter trial (NCT03666143), expected to include 100 patients with advanced ovarian, lung, and kidney cancers, is being conducted in China and Australia. It is part of a collaboration between Mirati and BeiGene. "We're excited to move into the next phase of our collaboration with BeiGene. BeiGene's ability to rapidly enroll patients into this clinical trial has the potential to significantly expand and accelerate our development efforts for sitravatinib and provide access to additional patient populations," Charles Baum, MD, PhD, president and CEO of Mirati, said in a press release. "This clinical trial also has the potential to provide proof of concept clinical data in multiple solid tumor types." Sitravatinib is an inhibitor of tyrosine kinase receptors, essential players in multiple cell processes, including cell proliferation, differentiation, cell death, and cell-to-cell communication. Specifically, the molecule is a potent inhi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *